A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease
This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria apply.
Stanford, California 94304, United States
New York, New York 10032, United States
Portland, Oregon 97239, United States
Dallas, Texas 75390-8527, United States
Houston, Texas 77030-4009, United States
Buenos Aires, Buenos Aires C1232AAC, Argentina
Buenos Aires, Buenos Aires C1405BCH, Argentina
Capital Federal, Buenos Aires 1425EKP, Argentina
Grenoble Cédex 9, 38043, France
Balcova / Izmir, 35340, Turkey (Türkiye)
Fatih / Istanbul, 34098, Turkey (Türkiye)